» Articles » PMID: 17308072

Sensitization of P53-mutated Epithelial Ovarian Cancer to CD95-mediated Apoptosis is Synergistically Induced by Cisplatin Pretreatment

Overview
Journal Mol Cancer Ther
Date 2007 Feb 20
PMID 17308072
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial ovarian carcinoma (EOC) remains a highly lethal malignancy. Despite the progress in surgical and therapeutic strategies, resistance to chemotherapy is still a major concern. Cytotoxic therapies mediate killing of cancer cells by activating the intrinsic mitochondrial apoptotic pathway, and p53 status is a key factor in determining the efficacy of apoptotic signaling. The extrinsic (CD95) death receptor-dependent signaling pathway also contributes to the efficacy of cancer therapy. We previously showed that EOC are generally resistant to CD95-dependent apoptosis. In p53 wild-type EOC tumors, CD95-mediated apoptosis is impaired at the receptor level by the long form of cellular FLICE-inhibitory protein, whereas this mechanism does not account for resistance in tumors with mutated p53 (p53mu). In the present study, we examined both intrinsic and death receptor-dependent apoptotic signaling in p53mu OVCAR3 EOC cell line, showing that these cells are less susceptible to cisplatin treatment as compared with p53 wild-type EOC cells and also resist CD95-mediated apoptosis due to inefficient formation of the death-inducing signaling complex and weak mitochondrial signal amplification. However, pretreatment of OVCAR3 cells with clinically relevant cisplatin concentrations significantly improved receptor-dependent apoptotic signaling by up-modulating CD95 receptor expression and increasing death-inducing signaling complex formation efficiency. The synergy of cisplatin pretreatment and CD95 triggering in inducing cell death was also shown in p53mu tumor cells derived from ascitic fluid of advanced-stage EOC patients. These findings support the effectiveness of a combined therapeutic treatment able to sensitize cancer cells to apoptosis even when p53 is functionally inactivated.

Citing Articles

Kinetin Ameliorates Cisplatin-Induced Hepatotoxicity and Lymphotoxicity via Attenuating Oxidative Damage, Cell Apoptosis and Inflammation in Rats.

Fathy M, A Darwish M, Abdelhamid A, Alrashedy G, Othman O, Naseem M Biomedicines. 2022; 10(7).

PMID: 35884925 PMC: 9312964. DOI: 10.3390/biomedicines10071620.


Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells.

Rizzo A, Satta A, Garrone G, Cavalleri A, Napoli A, Raspagliesi F J Exp Clin Cancer Res. 2021; 40(1):5.

PMID: 33390181 PMC: 7780408. DOI: 10.1186/s13046-020-01794-6.


Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells.

Al-Qatati A, Aliwaini S Oncol Lett. 2018; 14(6):7993-7999.

PMID: 29344241 PMC: 5755017. DOI: 10.3892/ol.2017.7189.


Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.

Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P Oncotarget. 2012; 2(12):1265-78.

PMID: 22246208 PMC: 3282083. DOI: 10.18632/oncotarget.401.


Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.

Symes J, Siatskas C, Fowler D, Medin J Cancer Gene Ther. 2008; 16(5):439-52.

PMID: 19096446 PMC: 2857530. DOI: 10.1038/cgt.2008.96.